Literature DB >> 18632923

Lipoteichoic acid synergizes with glycosphingolipids to potently stimulate secretion of interleukin-6 from human blood cells.

Shiri Meron-Sudai1, Ariella Matityahou, Yona Keisari, Kathleen H Cox, David L Hasty, Itzhak Ofek.   

Abstract

In the present study, we found that lipoteichoic acid (LTA) synergizes with glycosphingolipids to stimulate human blood cells to secrete cytokines. We employed globoside, kerasin, and lactosylceramide as representative neutral glycosphingolipids and mixed gangliosides GM(2) and GM(3) as representative acidic glycosphingolipids. LTA and the glycosphingolipids enhanced cytokine secretion by human whole blood, peripheral blood mononuclear cells, and purified monocytes in a dose-dependent manner. The level of synergy ranged up to approximately 10-fold greater than the additive stimulation caused by LTA and glycosphingolipid alone. The greatest synergy was observed with GM(3). We also found that LTA synergizes with the synthetic bacterial lipopeptide mimic Pam3CysK4. In contrast, the glycosphingolipids suppressed the stimulation caused by Pam3CysK4. The stimulation of human cells requires the simultaneous presence of LTA and the glycosphingolipids and probably requires their physical interactions, as shown by dot blotting and nondenaturing polyacrylamide gel electrophoresis experiments. We hypothesize that the enhanced stimulation is due to heterooligomers that form between LTA and glycosphingolipids at the subcritical micelle concentrations used in these experiments. Previous studies showed that LTA also synergizes with hemoglobin. The data taken together suggest that LTA may be a pathogen-associated molecular pattern, although its full activity requires the presence of a synergistic partner(s).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632923      PMCID: PMC2546685          DOI: 10.1128/CVI.00060-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  30 in total

1.  Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture.

Authors:  S Yang; R Tamai; S Akashi; O Takeuchi; S Akira; S Sugawara; H Takada
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 2.  Bacterial lipopolysaccharides and innate immunity.

Authors:  C Alexander; E T Rietschel
Journal:  J Endotoxin Res       Date:  2001

3.  Enhancement of macrophage stimulation by lipoteichoic acid and the costimulant hemoglobin is dependent on Toll-like receptors 2 and 4.

Authors:  Kathleen H Cox; Itzhak Ofek; David L Hasty
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

4.  Lipoteichoic acid and toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent.

Authors:  Martha Triantafilou; Maria Manukyan; Alan Mackie; Siegfried Morath; Thomas Hartung; Holger Heine; Kathy Triantafilou
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

Review 5.  Structural and functional analyses of bacterial lipopolysaccharides.

Authors:  Martine Caroff; Doris Karibian; Jean Marc Cavaillon; Nicole Haeffner-Cavaillon
Journal:  Microbes Infect       Date:  2002-07       Impact factor: 2.700

6.  Evidence of immunostimulating lipoprotein existing in the natural lipoteichoic acid fraction.

Authors:  Masahito Hashimoto; Maiko Furuyashiki; Ryoko Kaseya; Yuka Fukada; Mai Akimaru; Kazue Aoyama; Toshiomi Okuno; Toshihide Tamura; Teruo Kirikae; Fumiko Kirikae; Nobutaka Eiraku; Hirofumi Morioka; Yukari Fujimoto; Koichi Fukase; Katsuhiro Takashige; Yoichiro Moriya; Shoichi Kusumoto; Yasuo Suda
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

Review 7.  Endotoxins: relationships between structure, function, and activity.

Authors:  Klaus Brandenburg; Andre Wiese
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

8.  A new kind of carbohydrate array, its use for profiling antiglycan antibodies, and the discovery of a novel human cellulose-binding antibody.

Authors:  Mikael Schwarz; Larissa Spector; Ari Gargir; Avraham Shtevi; Monica Gortler; Rom T Altstock; Avinoam A Dukler; Nir Dotan
Journal:  Glycobiology       Date:  2003-07-08       Impact factor: 4.313

9.  Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus.

Authors:  S Morath; A Geyer; T Hartung
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

10.  Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release.

Authors:  Siegfried Morath; Andreas Stadelmaier; Armin Geyer; Richard R Schmidt; Thomas Hartung
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

View more
  5 in total

1.  Lactobacillus plantarum lipoteichoic acid alleviates TNF-α-induced inflammation in the HT-29 intestinal epithelial cell line.

Authors:  Hangeun Kim; Bong Jun Jung; Ji Hae Jung; Joo Yun Kim; Sung Kyun Chung; Dae Kyun Chung
Journal:  Mol Cells       Date:  2012-04-17       Impact factor: 5.034

2.  Lipoteichoic acid from Staphylococcus aureus exacerbates respiratory disease in porcine respiratory coronavirus-infected pigs.

Authors:  Kalina Atanasova; Steven Van Gucht; Filip Barbé; Luc Duchateau; Kristien Van Reeth
Journal:  Vet J       Date:  2010-04-20       Impact factor: 2.688

3.  Lipoprotein lipase and hydrofluoric acid deactivate both bacterial lipoproteins and lipoteichoic acids, but platelet-activating factor-acetylhydrolase degrades only lipoteichoic acids.

Authors:  Ho Seong Seo; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2009-06-24

4.  Systematic review of membrane components of gram-positive bacteria responsible as pyrogens for inducing human monocyte/macrophage cytokine release.

Authors:  Christoph Rockel; Thomas Hartung
Journal:  Front Pharmacol       Date:  2012-04-17       Impact factor: 5.810

5.  MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216.

Authors:  Joannes A A Reijers; D G Kallend; K E Malone; J W Jukema; P L J Wijngaard; J Burggraaf; M Moerland
Journal:  Cardiovasc Drugs Ther       Date:  2017-08       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.